Reduction in 10-year risk of major CVD end points (CHD death/nonfatal MI) in major statin trials, or substudies of major trials, in diabetic subjects (n = 16,032)
| Study (ref.) | CVD prevention | Statin dose and comparator | RRR | ARR | LDL cholesterol reduction |
|---|---|---|---|---|---|
| 4S-DM (155) | 20 | Simvastatin 20–40 mg vs. placebo | 85.7 to 43.2% (50%) | 42.5% | 186 to 119 mg/dl (36%) |
| ASPEN 20 (160) | 20 | Atorvastatin 10 mg vs. placebo | 39.5 to 24.5% (34%) | 12.7% | 112 to 79 mg/dl (29%) |
| HPS-DM (156) | 20 | Simvastatin 40 mg vs. placebo | 43.8 to 36.3% (17%) | 7.5% | 123 to 84 mg/dl (31%) |
| CARE-DM (157) | 20 | Pravastatin 40 mg vs. placebo | 40.8 to 35.4% (13%) | 5.4% | 136 to 99 mg/dl (27%) |
| TNT-DM (158) | 20 | Atorvastatin 80 mg vs. 10 mg | 26.3 to 21.6% (18%) | 4.7% | 99 to 77 mg/dl (22%) |
| HPS-DM (156) | 10 | Simvastatin 40 mg vs. placebo | 17.5 to 11.5% (34%) | 6.0% | 124 to 86 mg/dl (31%) |
| CARDS (161) | 10 | Atorvastatin 10 mg vs. placebo | 11.5 to 7.5% (35%) | 4% | 118 to 71 mg/dl (40%) |
| ASPEN 10 (160) | 10 | Atorvastatin 10 mg vs. placebo | 11.0 to 7.9% (19%) | 1.9% | 114 to 80 mg/dl (30%) |
| ASCOT-DM (159) | 10 | Atorvastatin 10 mg vs. placebo | 11.1 to 10.2% (8%) | 0.9% | 125 to 82 mg/dl (34%) |
Studies were of differing lengths (3.3–5.4 years) and used somewhat different outcomes, but all reported rates of CVD death and nonfatal MI. In this tabulation, results of the statin on 10-year risk of major CVD end points (CHD death/nonfatal MI) are listed for comparison between studies. Correlation between 10-year CVD risk of the control group and the ARR with statin therapy is highly significant (P = 0.0007). Analyses provided by Craig Williams, Pharm.D., Oregon Health & Science University, 2007. ARR, absolute risk reduction; RRR, relative risk reduction.